Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs

Published:2007 Issue:6 Volume:25 Page:481-496
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Darkow Theodore,Henk Henry J,Thomas Simu K,Feng Weiwei,Baladi Jean-Francois,Goldberg George A,Hatfield Alan,Cortes Jorge

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Reference45 articles.

1. Imatinib Mesylate, the First Molecularly Targeted Gene Suppressor

2. Imatinib Mesylate — A New Oral Targeted Therapy

3. Imatinib mesylate—gold standards and silver linings

4. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study

Cited by 230 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

2. Advancing personalized medicine with 3D printed combination drug therapies: A comprehensive review of application in various conditions;European Polymer Journal;2024-07

3. Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges?;The AAPS Journal;2024-06-11

4. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

5. Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients;Journal of Oncology Pharmacy Practice;2023-11-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3